Glutathione

Overview

Glutathione (GSH) is a tripeptide composed of three amino acids in an unusual configuration. The bond between glutamate and cysteine forms through the gamma-carboxyl group of glutamate rather than the standard alpha-carboxyl, producing a peptide that is resistant to nearly all peptidases. That structural feature is the basis for the molecule’s long intracellular half-life. The cysteine residue carries a reactive thiol group that is the chemical heart of glutathione’s function as an antioxidant and conjugating substrate.

Glutathione is the most abundant low-molecular-weight thiol in mammalian cells, present at millimolar concentrations in the cytosol of most tissues. The intracellular pool is dominated by the reduced form (GSH); the oxidized disulfide form (GSSG) is continuously recycled by glutathione reductase using NADPH as the electron donor. The GSH-to-GSSG ratio is a widely used measure of cellular redox state.

The tripeptide functions as a substrate for several enzyme families that handle oxidative and xenobiotic stress, including glutathione peroxidases (which reduce hydrogen peroxide and lipid peroxides), glutathione S-transferases (which conjugate electrophilic xenobiotics for biliary or urinary excretion), and thiol-disulfide oxidoreductases. Cellular glutathione depletion has been documented in hepatic injury, neurodegeneration, and several oxidative-stress-driven pathologies.

Mechanism of Action

Direct ROS Scavenging

The cysteine thiol of glutathione donates a hydrogen atom to reactive oxygen species, producing the thiyl radical (GS), which dimerizes with a second molecule to form oxidized glutathione (GSSG). This nonenzymatic chemistry contributes to the buffering of acute oxidative stress.

Enzymatic Detoxification

Glutathione peroxidases (GPx 1-8) catalyze reduction of hydrogen peroxide and organic peroxides using GSH as the reducing substrate. Glutathione S-transferases (GSTs) catalyze conjugation of GSH to electrophilic centers on xenobiotic molecules, producing more polar, excretable derivatives. Both enzyme families are central to the hepatic Phase II detoxification pathway described in classical pharmacology.

Heavy Metal Chelation

The cysteine thiol forms strong coordination bonds with soft Lewis acids including mercury, cadmium, copper, and arsenic. Glutathione mediates a substantial portion of cellular heavy metal sequestration and biliary excretion.

Protein S-Glutathionylation

Glutathione forms reversible mixed disulfides with protein cysteine residues, a post-translational modification termed S-glutathionylation. This modification serves as a redox-sensitive signaling mechanism distinct from the molecule’s bulk antioxidant role.

Research Summary

Hepatic Detoxification

Meister (1988, Annual Review of Biochemistry) reviewed the central role of glutathione in hepatic xenobiotic handling, work that has remained foundational. Acetaminophen overdose, the most common cause of acute liver failure, depletes hepatic glutathione, and the clinical antidote N-acetylcysteine (NAC) acts by providing cysteine for resynthesis of GSH.

Parkinson’s Disease and Neurodegeneration

Sechi et al. (1996, Progress in Neuro-Psychopharmacology and Biological Psychiatry) reported clinical improvements in Parkinson’s disease patients receiving intravenous glutathione. Allen et al. (2011, Integrative Medicine) reviewed subsequent IV glutathione work, noting variable methodological quality and a need for larger controlled trials. Pizzorno (2014) provides a frequently cited review of the broader glutathione clinical literature.

Bioavailability Considerations

Oral glutathione has poor bioavailability, the tripeptide is hydrolyzed in the gut and absorbed predominantly as its constituent amino acids, which are then resynthesized into GSH within cells. This has driven interest in cysteine precursors (NAC, gamma-glutamylcysteine), liposomal glutathione formulations, and parenteral routes.

Skin Pigmentation

Glutathione’s apparent effect on melanin production has driven a consumer market for oral, topical, and IV glutathione as a skin-lightening agent, particularly in parts of Asia. The peer-reviewed evidence is limited and the FDA has issued warnings about injectable glutathione products marketed for cosmetic skin lightening.

Research Status

Glutathione is an endogenous tripeptide and is well established biochemically. As an exogenous therapeutic, the published clinical literature is concentrated in Parkinson’s disease, hepatic injury (where NAC is the standard adjunct), and oxidative-stress-related conditions. Direct IV glutathione for research purposes carries the sterility and infection considerations of any injectable preparation. Skin-lightening marketing claims are not supported by FDA-approved indications.

Further reading: Glutathione: Antioxidant Research and Delivery Formats reviews the antioxidant literature and how delivery format affects bioavailability.

Dosing in Published Research

Glutathione is an antioxidant molecule produced naturally by the body. It is also sold as a dietary supplement and is used in some unapproved intravenous regimens, but it is not an FDA-approved drug for general use, so it has no labeled therapeutic dose. Doses that appear in the research literature include oral supplementation studies using roughly 250 to 1,000 mg per day over several months, and a small intravenous pilot study in Parkinson disease that used about 1,400 mg three times weekly. These figures describe what was administered in those specific studies.

Frequently Asked Questions